Jounce Therapeutics, Inc. (JNCE) Rating Increased to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of Jounce Therapeutics, Inc. (NASDAQ:JNCE) from a sell rating to a hold rating in a research note published on Wednesday morning.

According to Zacks, “Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. It engaged in developing therapies which enable the immune system to attack tumors. The Company’s lead product candidate, JTX-2011, is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of certain T cells found in a range of solid tumors. It also developing JTX-4014 for use in future combinations with JTX-2011, as well as for use in combination with other future product candidates. Jounce Therapeutics, Inc. is based in Cambridge, United States. “

JNCE has been the subject of several other research reports. J P Morgan Chase & Co set a $28.00 price objective on Jounce Therapeutics and gave the company a buy rating in a research note on Monday, November 13th. Robert W. Baird reiterated an outperform rating and issued a $30.00 price objective on shares of Jounce Therapeutics in a research note on Monday, September 18th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Jounce Therapeutics has an average rating of Buy and an average price target of $23.67.

Jounce Therapeutics (NASDAQ:JNCE) opened at $14.59 on Wednesday. Jounce Therapeutics has a 52 week low of $11.05 and a 52 week high of $29.29.

Jounce Therapeutics (NASDAQ:JNCE) last announced its quarterly earnings data on Monday, November 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.12. The business had revenue of $18.10 million during the quarter, compared to analysts’ expectations of $20.00 million. Jounce Therapeutics had a negative return on equity of 1.66% and a negative net margin of 2.03%. The company’s revenue was up 7.1% compared to the same quarter last year. equities research analysts forecast that Jounce Therapeutics will post -0.76 EPS for the current fiscal year.

WARNING: This article was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://ledgergazette.com/2017/11/19/jounce-therapeutics-inc-jnce-rating-increased-to-hold-at-zacks-investment-research.html.

A number of hedge funds have recently bought and sold shares of JNCE. Fosun International Ltd lifted its stake in Jounce Therapeutics by 208.8% during the third quarter. Fosun International Ltd now owns 285,960 shares of the company’s stock worth $4,455,000 after purchasing an additional 193,350 shares during the last quarter. Brown Advisory Inc. lifted its stake in Jounce Therapeutics by 55.9% during the third quarter. Brown Advisory Inc. now owns 475,719 shares of the company’s stock worth $7,411,000 after purchasing an additional 170,661 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in Jounce Therapeutics during the second quarter worth approximately $2,359,000. Vanguard Group Inc. lifted its stake in Jounce Therapeutics by 123.8% during the second quarter. Vanguard Group Inc. now owns 255,060 shares of the company’s stock worth $3,578,000 after purchasing an additional 141,096 shares during the last quarter. Finally, Conning Inc. purchased a new stake in Jounce Therapeutics during the second quarter worth approximately $1,299,000. Hedge funds and other institutional investors own 44.47% of the company’s stock.

Jounce Therapeutics Company Profile

Jounce Therapeutics, Inc is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient.

Get a free copy of the Zacks research report on Jounce Therapeutics (JNCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Jounce Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply